Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric Phase I/II Study for the Efficacy of a Combination of Rituximab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Indolent Lymphoma

NCT00954005 is registered in ClinicalTrials.gov with German Low Grade Lymphoma Study Group as lead sponsor.

NCT NCT00954005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00954005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric Phase I/II Study for the Efficacy of a Combination of Rituximab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Indolent Lymphoma
Lead sponsor
German Low Grade Lymphoma Study Group
Phase
Phase 1/2
Overall status
Terminated
Start date
January 31, 2003
Completion date
June 30, 2012
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

indolent lymphoma